Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer

  • Interventional
  • Not Recruiting
  • NCT01342354
Eligibility Details Visit Clinicaltrials.gov

A Phase I Study of Stereotactic Body Radiation Therapy in Patients With Unresected Carcinoma of the Pancreas or Ampulla

This purpose of this study is to determine the highest tolerated dose of Stereotactic Body Radiation Therapy (SBRT) and also to determine the appropriate dose for intact pancreatic cancer.

Gender
All

Age Group
18 Years and up

Accepting Healthy Volunteers?
No

Inclusion Criteria:

         - Patients must have histologically confirmed, unresected cancer of the pancreas or ampulla. The cancer may include any invasive histology (e.g. adenocarcinoma, neuroendocrine carcinoma).

         - Patients must have measurable radiographic disease.Patients with previous complete resection are only eligible if there is measurable radiographic disease which is clearly felt to represent locally recurrent disease.

         - Patients may receive any number of cycles of chemotherapy prior to treatment with SBRT, but not within 2 weeks of the first fraction of RT.

         - Age > or = 18 years.

         - Eastern Cooperative Oncology Group (ECOG) performance status < or = 2 (Karnofsky > or = 60%)

         - Life expectancy of greater than 3 months.

         - Patients must have normal organ and marrow function.

         - Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

         - Concurrent investigational therapy delivered over the period of treatment or observation (28 days post-RT) for dose limiting toxicity.

         - Prior radiation therapy to the abdominal area which would overlap with the proposed area of treatment.

         - Pregnancy.

         - Primary disease > 7.5 cm in largest diameter as measured by CT or MRI.

         - Gross extension of tumor into the lumen of the duodenum.

         - Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

         - Use of bevacizumab or vascular endothelial growth factor inhibitor chemotherapy within 3 months before RT or 6 months after RT.

At a Glance

National Government IDNCT01342354

IRB#16866B

Lead SponsorUniversity of Chicago

Lead PhysicianStanley Liauw

Collaborator(s)N/A

EligibilityAll
18 Years and up
Not Recruiting